CoChat
Sign Up
Cited by 121

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation, and leukemogenesis

Rosmarin, Alan G., Yang, Zhongfa, Resendes, Karen K.·2005·Experimental Hematology
DOI 10.1016/j.exphem.2004.08.015
Open this paper in CoChat — free account

Abstract

Myeloid cells (granulocytes and monocytes) are derived from multipotent hematopoietic stem cells. Gene transcription plays a critical role in hematopoietic differentiation. However, there is no single transcription factor that is expressed exclusively by myeloid cells and that, alone, acts as a "master" regulator of myeloid fate choice. Rather, myeloid gene expression is controlled by the combinatorial effects of several key transcription factors. Hematopoiesis has traditionally been viewed as linear and hierarchical, but there is increasing evidence of plasticity during blood cell development. Transcription factors strongly influence cellular lineage during hematopoiesis and expression of some transcription factors can alter the fate of developing hematopoietic progenitor cells. PU.1 and CCAAT/enhancer-binding protein alpha (C/EBPalpha) regulate expression of numerous myeloid genes, and gene disruption studies have shown that they play essential, nonredundant roles in myeloid cell development. They function in cooperation with other transcription factors, co-activators, and co-repressors to regulate genes in the context of chromatin. Because of their essential roles in regulating myeloid genes and in myeloid cell development, it has been hypothesized that abnormal expression of PU.1 and C/EBPalpha would contribute to aberrant myeloid differentiation, i.e. acute leukemia. Such a direct link has been elusive until recently. However, there is now persuasive evidence that mutati…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.exphem.2004.08.015

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 35 references

Research works printed but not linked: 124

  1. Shivdasani, 1996, The transcriptional control of hematopoiesis, Blood, 87, 4025, 10.1182/blood.V87.10.4025.bloodjournal87104025 · DOI · Paper page
  2. Zhu, 2002, Hematopoietic cytokines, transcription factors and lineage commitment, Oncogene, 21, 3295, 10.1038/sj.onc.1205318 · DOI
  3. Friedman, 2002, Transcriptional regulation of granulocyte and monocyte development, Oncogene, 21, 3377, 10.1038/sj.onc.1205324 · DOI
  4. Skalnik, 2002, Transcriptional mechanisms regulating myeloid-specific genes, Gene, 284, 1, 10.1016/S0378-1119(02)00387-6 · DOI
  5. Fuchs, 2000, Stem cells: a new lease on life, Cell, 100, 143, 10.1016/S0092-8674(00)81691-8 · DOI
  6. Weissman, 2000, Stem cells: units of development, units of regeneration, and units in evolution, Cell, 100, 157, 10.1016/S0092-8674(00)81692-X · DOI
  7. Kondo, 1997, Identification of clonogenic common lymphoid progenitors in mouse bone marrow, Cell, 91, 661, 10.1016/S0092-8674(00)80453-5 · DOI · Paper page
  8. Allman, 2002, An invitation to T and more: notch signaling in lymphopoiesis, Cell, 109, S1, 10.1016/S0092-8674(02)00689-X · DOI
  9. Herzog, 2003, Plasticity of marrow-derived stem cells, Blood, 102, 3483, 10.1182/blood-2003-05-1664 · DOI
  10. Quesenberry, 2004, Stem cell plasticity: an overview, Blood Cells Mol Dis, 32, 1, 10.1016/j.bcmd.2003.09.007 · DOI
  11. Enver, 1998, Do stem cells play dice?, Blood, 92, 348, 10.1182/blood.V92.2.348 · DOI
  12. Metcalf, 1998, Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation, Blood, 92, 345, 10.1182/blood.V92.2.345b · DOI
  13. Brown, 1988, The development of cell lineages: a sequential model, Differentiation, 39, 83, 10.1111/j.1432-0436.1988.tb00084.x · DOI
  14. Quesenberry, 2002, The chiaroscuro stem cell: a unified stem cell theory, Blood, 100, 4266, 10.1182/blood-2002-04-1246 · DOI
  15. Kirkland, 2004, A phase space model of hemopoiesis and the concept of stem cell renewal, Exp Hematol, 32, 511, 10.1016/j.exphem.2004.02.013 · DOI
  16. Perkins, 1991, Patterns of Evi-1 expression in embryonic and adult tissues suggest that Evi-1 plays an important regulatory role in mouse development, Development, 111, 479, 10.1242/dev.111.2.479 · DOI
  17. Bond, 1998, Identification by differential display of transcripts regulated during hematopoietic differentiation, Stem Cells, 16, 136, 10.1002/stem.160136 · DOI
  18. Tsai, 2000, Mouse Jagged2 is differentially expressed in hematopoietic progenitors and endothelial cells and promotes the survival and proliferation of hematopoietic progenitors by direct cell-to-cell contact, Blood, 96, 950, 10.1182/blood.V96.3.950 · DOI
  19. Phillips, 2000, The genetic program of hematopoietic stem cells, Science, 288, 1635, 10.1126/science.288.5471.1635 · DOI
  20. Ivanova, 2002, A stem cell molecular signature, Science, 298, 601, 10.1126/science.1073823 · DOI
  21. Hu, 1997, Multilineage gene expression precedes commitment in the hemopoietic system, Genes Dev, 11, 774, 10.1101/gad.11.6.774 · DOI
  22. Billia, 2001, Resolution of pluripotential intermediates in murine hematopoietic differentiation by global complementary DNA amplification from single cells: confirmation of assignments by expression profiling of cytokine receptor transcripts, Blood, 97, 2257, 10.1182/blood.V97.8.2257 · DOI
  23. Miyamoto, 2002, Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment, Dev Cell, 3, 137, 10.1016/S1534-5807(02)00201-0 · DOI · Paper page
  24. Ye, 2003, Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential, Immunity, 19, 689, 10.1016/S1074-7613(03)00299-1 · DOI
  25. Chen, 1995, PU.1 (Spi-1) autoregulates its expression in myeloid cells, Oncogene, 11, 1549
  26. Boyd, 1982, Derivation of macrophage-like lines from the pre-B lymphoma ABLS 8.1 using 5-azacytidine, Nature, 297, 691, 10.1038/297691a0 · DOI
  27. Klinken, 1988, Hemopoietic lineage switch: v-raf oncogene converts Emu-myc transgenic B cells into macrophages, Cell, 53, 857, 10.1016/S0092-8674(88)90309-1 · DOI
  28. Borzillo, 1990, Macrophage lineage switching of murine early pre-B lymphoid cells expressing transduced fms genes, Mol Cell Biol, 10, 2703
  29. Iwasaki-Arai, 2003, Enforced granulocyte/macrophage colony-stimulating factor signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion, J Exp Med, 197, 1311, 10.1084/jem.20021843 · DOI
  30. Kondo, 2000, Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines, Nature, 407, 383, 10.1038/35030112 · DOI
  31. Lassar, 1986, Transfection of a DNA locus that mediates the conversion of 10T1/2 fibroblasts to myoblasts, Cell, 47, 649, 10.1016/0092-8674(86)90507-6 · DOI
  32. Choi, 1990, MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes, Proc Natl Acad Sci USA, 87, 7988, 10.1073/pnas.87.20.7988 · DOI
  33. Mikkola, 2002, Reversion of B cell commitment upon loss of Pax5 expression, Science, 297, 110, 10.1126/science.1067518 · DOI
  34. Nutt, 1999, Commitment to the B-lymphoid lineage depends on the transcription factor Pax5, Nature, 401, 556, 10.1038/44076 · DOI
  35. Heavey, 2003, Myeloid lineage switch of Pax5 mutant but not wild-type B cell progenitors by C/EBPalpha and GATA factors, EMBO J, 22, 3887, 10.1093/emboj/cdg380 · DOI
  36. Heyworth, 2002, Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells, EMBO J, 21, 3770, 10.1093/emboj/cdf368 · DOI
  37. Xie, 2004, Stepwise reprogramming of B cells into macrophages, Cell, 117, 663, 10.1016/S0092-8674(04)00419-2 · DOI
  38. Jenuwein, 2001, Translating the histone code, Science, 293, 1074, 10.1126/science.1063127 · DOI · Paper page
  39. Blobel, 2002, CREB-binding protein and p300: molecular integrators of hematopoietic transcription, Blood, 95, 745, 10.1182/blood.V95.3.745.003k05_745_755 · DOI
  40. Yamaguchi, 2004, AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues, J Biol Chem, 279, 15630, 10.1074/jbc.M400355200 · DOI
  41. Schwartz, 2003, Recruitment of p300 by C/EBPbeta triggers phosphorylation of p300 and modulates coactivator activity, EMBO J, 22, 882, 10.1093/emboj/cdg076 · DOI
  42. Melnick, 2002, Histone deacetylases as therapeutic targets in hematologic malignancies, Curr Opin Hematol, 9, 322, 10.1097/00062752-200207000-00010 · DOI
  43. Zhang, 2003, Structural basis for the product specificity of histone lysine methyltransferases, Mol Cell, 12, 177, 10.1016/S1097-2765(03)00224-7 · DOI
  44. Kontaraki, 2000, Chromatin fine structure profiles for a developmentally regulated gene: reorganization of the lysozyme locus before trans-activator binding and gene expression, Genes Dev, 14, 2106, 10.1101/gad.14.16.2106 · DOI
  45. Lefevre, 2001, Identification of factors mediating the developmental regulation of the early acting −3.9 kb chicken lysozyme enhancer element, Nucleic Acids Res, 29, 4551, 10.1093/nar/29.22.4551 · DOI
  46. Tagoh, 2004, Dynamic reorganization of chromatin structure and selective DNA demethylation prior to stable enhancer complex formation during differentiation of primary hematopoietic cells in vitro, Blood, 103, 2950, 10.1182/blood-2003-09-3323 · DOI
  47. Sobulo, 1997, MLL is fused to CBP, a histone acetyltransferase, in therapy- related acute myeloid leukemia with a t(11;16)(q23;p13.3), Proc Natl Acad Sci USA, 94, 8732, 10.1073/pnas.94.16.8732 · DOI
  48. Kelly, 2002, Genetics of myeloid leukemias, Annu Rev Genomics Hum Genet, 3, 179, 10.1146/annurev.genom.3.032802.115046 · DOI
  49. Nunn, 1983, Tripartite structure of the avain erythroblastosis virus E26 transforming gene, Nature, 306, 391, 10.1038/306391a0 · DOI
  50. Leprince, 1983, A putative second cell-derived oncogene of the avian leukaemia retrovirus E26, Nature, 306, 395, 10.1038/306395a0 · DOI
  51. Donaldson, 1996, Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif, EMBO J, 15, 125, 10.1002/j.1460-2075.1996.tb00340.x · DOI
  52. Wemer, 1995, The solution structure of the human ETS1-DNA complex reveals a novel mode of binding and true side chain intercalation, Cell, 83, 761, 10.1016/0092-8674(95)90189-2 · DOI
  53. Wasylyk, 1993, The Ets family of transcription factors, Eur J Biochem, 211, 7, 10.1111/j.1432-1033.1993.tb19864.x · DOI
  54. Sharrocks, 1997, The ETS-domain transcription factor family, Int J Biochem Cell Biol, 29, 1371, 10.1016/S1357-2725(97)00086-1 · DOI
  55. Oikawa, 2003, Molecular biology of the Ets family of transcription factors, Gene, 303, 11, 10.1016/S0378-1119(02)01156-3 · DOI
  56. Moreau-Gachelin F, Ray D, Mattei MG, Tambourin P, Tavitian A. The putative oncogene Spi-1: murine chromosomal localization and transcriptional activation in murine acute erythroleukemias. Oncogene. 1989;4:1449–1456. Erratum in Oncogene 1990;5:1611–1612.
  57. Paul, 1991, The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1, J Virol, 65, 464, 10.1128/jvi.65.1.464-467.1991 · DOI · Paper page
  58. Klemsz, 1990, The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene, Cell, 61, 113, 10.1016/0092-8674(90)90219-5 · DOI · Paper page
  59. Rosmarin, 1995, CD18 (β2 leukocyte integrin) promoter requires PU.1 transcription factor for myeloid activity, Proc Natl Acad Sci USA, 92, 801, 10.1073/pnas.92.3.801 · DOI
  60. Reddy, 1994, Opposing actions of c-ets/PU.1 and c-myb protooncogene products in regulating the macrophage-specific promoters of the human and mouse colony-stimulating factor-1 receptor (c-fms) genes, J Exp Med, 180, 2309, 10.1084/jem.180.6.2309 · DOI · Paper page
  61. Scott, 1994, Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages, Science, 265, 1573, 10.1126/science.8079170 · DOI · Paper page
  62. McKercher, 1996, Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities, EMBO J, 15, 5647, 10.1002/j.1460-2075.1996.tb00949.x · DOI · Paper page
  63. Henkel, 1996, PU.1 but not ets-2 is essential for macrophage development from embryonic stem cells, Blood, 88, 2917, 10.1182/blood.V88.8.2917.bloodjournal8882917 · DOI · Paper page
  64. Anderson, 1998, Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent, Blood, 92, 1576, 10.1182/blood.V92.5.1576 · DOI
  65. Henkel, 1999, Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1, Blood, 93, 2849, 10.1182/blood.V93.9.2849.409a12_2849_2858 · DOI
  66. Iwama, 1998, Use of RDA analysis of knockout mice to identify myeloid genes regulated in vivo by PU.1 and C/EBP alpha, Nucleic Acids Res, 26, 3034, 10.1093/nar/26.12.3034 · DOI · Paper page
  67. DeKoter, 2000, Regulation of B lymphocyte and macrophage development by graded expression of PU.1, Science, 288, 1439, 10.1126/science.288.5470.1439 · DOI · Paper page
  68. Shibata, 2001, GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1, Immunity, 15, 557, 10.1016/S1074-7613(01)00218-7 · DOI
  69. Bjerregaard, 2003, The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow, Blood, 101, 4322, 10.1182/blood-2002-03-0835 · DOI
  70. Lord, 1993, Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation, Mol Cell Biol, 13, 841
  71. Szabo, 1994, Constitutive cJun expression induces partial macrophage differentiation in U-937 cells, Cell Growth Differ, 5, 439
  72. Li, 1994, Differentiation of WEHI-3B D+ myelomonocytic leukemia cells induced by ectopic expression of the protooncogene c-jun, Cell Growth Differ, 5, 743
  73. Zhang, 1999, Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1, Proc Natl Acad Sci USA, 96, 8705, 10.1073/pnas.96.15.8705 · DOI · Paper page
  74. Yamada, 2001, Lineage switch induced by overexpression of Ets family transcription factor PU.1 in murine erythroleukemia cells, Blood, 97, 2300, 10.1182/blood.V97.8.2300 · DOI
  75. Mclvor, 2003, Transient expression of PU.1 commits multipotent progenitors to a myeloid fate whereas continued expression favors macrophage over granulocyte differentiation, Exp Hemato, 31, 39, 10.1016/S0301-472X(02)01017-2 · DOI
  76. Landschulz, 1989, The DNA binding domain of the rat liver nuclear protein C/EBP is bipartite, Science, 243, 1681, 10.1126/science.2494700 · DOI
  77. Friedman, 1989, CCAAT/enhancer binding protein activates the promoter of the serum albumin gene in cultured hepatoma cells, Genes Dev, 3, 1314, 10.1101/gad.3.9.1314 · DOI
  78. Friedman, 1990, Identification of two polypeptide segments of CCAAT/enhancer-binding protein required for transcriptional activation of the serum albumin gene, Genes Dev, 4, 1416, 10.1101/gad.4.8.1416 · DOI · Paper page
  79. Calkhoven, 2002, Translational control of C/EBPalpha and C/EBPbeta isoform expression, Genes Dev, 14, 1920, 10.1101/gad.14.15.1920 · DOI
  80. Descombes, 1991, A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA, Cell, 67, 569, 10.1016/0092-8674(91)90531-3 · DOI
  81. Scott, 1992, A novel temporal expression pattern of three C/EBP family members in differentiating Myelomonocytic Cells, Blood, 80, 1725, 10.1182/blood.V80.7.1725.1725 · DOI · Paper page
  82. Antonson, 1996, A novel human CCAAT/enhancer binding protein gene, C/EBPε1 is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor α/δ locus, Genomics, 35, 30, 10.1006/geno.1996.0319 · DOI
  83. Friedman, 1996, GADD153/CHOP, a DNA damage-inducible protein, reduced CAAT/enhancer binding protein activities and increased apoptosis in 32D cl3 myeloid cells, Cancer Res, 56, 3250
  84. Pan, 1999, CCAAT/enhancer-binding protein activates the CD14 promoter and mediates transforming growth factor beta signaling in monocyte development, J Biol Chem, 274, 23242, 10.1074/jbc.274.33.23242 · DOI
  85. Khanna-Gupta, 2000, Sp1 and C/EBP are necessary to activate the lactoferrin gene promoter during myeloid differentiation, Blood, 95, 3734, 10.1182/blood.V95.12.3734.012k27_3734_3741 · DOI
  86. Wang, 2002, C/EBPalpha and G-CSF receptor signals cooperate to induce the myeloperoxidase and neutrophil elastase genes, Leukemia, 15, 779, 10.1038/sj.leu.2402094 · DOI
  87. Faust, 1999, Differential activity of the −2.7 kb chicken lysozyme enhancer in macrophages of different ontogenic origins is regulated by C/EBP and PU.1 transcription factors, DNA Cell Biol, 18, 631, 10.1089/104454999315042 · DOI
  88. Gombart, 2003, Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP epsilon and PU.1, Blood, 101, 3265, 10.1182/blood-2002-04-1039 · DOI
  89. Verbeek, 1999, C/EBPepsilon directly interacts with the DNA binding domain of c-myb and cooperatively activates transcription of myeloid promoters, Blood, 93, 3327, 10.1182/blood.V93.10.3327 · DOI
  90. Wang, 1999, C/EBPα bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts, Blood, 94, 560, 10.1182/blood.V94.2.560 · DOI · Paper page
  91. Nakajima, 2001, Granulocyte colony-stimulating factor regulates myeloid differentiation through CCAAT/enhancer-binding protein epsilon, Blood, 98, 897
  92. Park, 1999, CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment, J Clin Invest, 103, 1399, 10.1172/JCI2887 · DOI · Paper page
  93. Wang, 2002, CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor, Blood, 99, 2776, 10.1182/blood.V99.8.2776 · DOI
  94. Khanna-Gupta, 2001, C/EBP epsilon mediates myeloid differentiation and is regulated by the CCAAT displacement protein (CDP/cut), Proc Natl Acad Sci USA, 98, 8000, 10.1073/pnas.141229598 · DOI
  95. Zhang, 2002, Induction of granulocytic differentiation by 2 pathways, Blood, 99, 4406, 10.1182/blood.V99.12.4406 · DOI
  96. Collins, 2001, Multipotent hematopoietic cell lines derived from C/EBPalpha(−/−) knockout mice display granulocyte macrophage-colony-stimulating factor, granulocyte-colony-stimulating factor, and retinoic acid-induced granulocytic differentiation, Blood, 98, 2382, 10.1182/blood.V98.8.2382 · DOI
  97. Screpanti I, Romani L, Musiani P, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J. 1995;14:1932–1941. Erratum in EMBO J. 1995;14:3596. · DOI · Paper page
  98. Tanaka, 1995, Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages, Cell, 80, 353, 10.1016/0092-8674(95)90418-2 · DOI
  99. Tanaka, 1997, Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene, EMBO J, 16, 7432, 10.1093/emboj/16.24.7432 · DOI
  100. Yamanaka, 1997, Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice, Proc Natl Acad Sci USA, 94, 13187, 10.1073/pnas.94.24.13187 · DOI · Paper page
  101. Lekstrom-Himes, 1999, Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/Enhancer binding protein epsilon, J Exp Med, 189, 1847, 10.1084/jem.189.11.1847 · DOI
  102. Gaines, 2003, Retinoids in myelopoiesis, J Biol Regul Homeost Agents, 17, 46
  103. Tsai, 1993, A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage, Proc Natl Acad Sci USA, 90, 7153, 10.1073/pnas.90.15.7153 · DOI
  104. Melnick, 1999, Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia, Blood, 93, 3167, 10.1182/blood.V93.10.3167.410k44_3167_3215 · DOI
  105. Huang, 1988, Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, 72, 567, 10.1182/blood.V72.2.567.567 · DOI
  106. Erickson, 1992, Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt, Blood, 80, 1825, 10.1182/blood.V80.7.1825.1825 · DOI · Paper page
  107. Liu, 1993, Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia, Science, 261, 1041, 10.1126/science.8351518 · DOI · Paper page
  108. Takahashi, 1995, Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2, Blood, 86, 607, 10.1182/blood.V86.2.607.bloodjournal862607 · DOI
  109. Cockerill, 1996, Regulation of GM-CSF gene transcription by core-binding factor, Cell Growth Differ, 7, 917
  110. Okuda, 1996, AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis, Cell, 84, 321, 10.1016/S0092-8674(00)80986-1 · DOI · Paper page
  111. Wang, 1996, Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis, Proc Natl Acad Sci USA, 93, 3444, 10.1073/pnas.93.8.3444 · DOI · Paper page
  112. Wang, 1996, The CBFβ subunit is essential for CBFα2 (AML1) function in vivo, Cell, 87, 697, 10.1016/S0092-8674(00)81389-6 · DOI · Paper page
  113. Castilla, 1996, Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11, Cell, 87, 687, 10.1016/S0092-8674(00)81388-4 · DOI · Paper page
  114. Pabst, 2001, Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia, Nat Genet, 27, 263, 10.1038/85820 · DOI · Paper page
  115. Gombart, 2002, Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias, Blood, 99, 1332, 10.1182/blood.V99.4.1332 · DOI
  116. Snaddon, 2003, Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2, Genes Chromosomes Cancer, 37, 72, 10.1002/gcc.10185 · DOI
  117. Preudhomme, 2002, Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA), Blood, 100, 2717, 10.1182/blood-2002-03-0990 · DOI
  118. Mueller, 2002, Heterozygous PU.1 mutations are associated with acute myeloid leukemia, Blood, 100, 998, 10.1182/blood.V100.3.998 · DOI · Paper page
  119. Brown, 1997, A PMLRARalpha transgene initiates murine acute promyelocytic leukemia, Proc Natl Acad Sci USA, 94, 2551, 10.1073/pnas.94.6.2551 · DOI
  120. Grisolano, 1997, Altered myeloid development and acute leukemia in transgenic mice expressing PML-RARα under control of cathepsin G regulatory sequences, Blood, 89, 376, 10.1182/blood.V89.2.376 · DOI
  121. He, 1997, Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice, Proc Natl Acad Sci USA, 94, 5302, 10.1073/pnas.94.10.5302 · DOI
  122. Cheng, 1999, Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha, Proc Natl Acad Sci USA, 96, 6318, 10.1073/pnas.96.11.6318 · DOI
  123. He, 1998, Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL, Nat Genet, 18, 126, 10.1038/ng0298-126 · DOI
  124. Downing, 2003, The core-binding factor leukemias: lessons learned from murine models, Curr Opin Genet Dev, 13, 48, 10.1016/S0959-437X(02)00018-7 · DOI

Cited by

Sorted by citations

See all 121

Metadata

Authors
Rosmarin, A. G., Yang, Z., & Resendes, K. K.
Venue
Experimental Hematology
Publisher
Elsevier BV
Published
2005-02
Volume
33
Issue
2
Pages
131-143
ISSN
0301-472X
DOI
10.1016/j.exphem.2004.08.015
Cited by
121
References
35
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review